Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline).
In-Ho Kim, Seung Joo Kang, Wonyoung Choi...
https://pubmed.ncbi.nlm.nih.gov/39822170Actively Recruiting
Phase Not Applicable
Age: 20Years +
All Genders
ID07161479
A Multicenter, Randomized, Single-Blinded Trial Comparing Argon Plasma Coagulation and Endoscopic Mucosal Resection for Gastric Adenoma With Low-Grade Dysplasia
Led by Samsung Medical Center · Updated on 2026-02-06
160
Participants Needed
3
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Gastric adenomas with low-grade dysplasia (LGD) are precancerous stomach lesions with a lower risk of progressing to cancer compared to high-grade dysplasia. This trial aims to compare two common endoscopic treatments, argon plasma coagulation (APC) and endoscopic mucosal resection (EMR), to see if APC is as effective as EMR in preventing local recurrence of these small lesions measuring 1 cm or less. The study addresses current uncertainties and differing international guidelines on managing these lesions. Participants will be randomly assigned to receive either APC, which uses ionized argon gas to coagulate tissue without cutting, or EMR, which involves lifting and cutting out the lesion. EMR allows detailed pathological examination but may take longer and have more complications, while APC is simpler, quicker, and usually less invasive but lacks tissue for pathology. After treatment, all participants receive standard medical care and are monitored for any complications. Participants will return for follow-up endoscopies at 3 and 12 months to check the treated area and take biopsies if needed to detect recurrence. Researchers will record the local recurrence rate at 12 months as the main outcome, along with procedure-related complications like bleeding or perforation, procedure time, and recovery experience. The trial will provide important evidence to guide treatment choices for patients with small gastric adenomas.
CONDITIONS
Brief Title
Argon Plasma Coagulation Versus Endoscopic Mucosal Resection for Gastric Adenoma (CLER-GA)
Who Can Participate
Age: 20Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Adults aged 20 years or older
- Diagnosed with gastric adenoma with low-grade dysplasia measuring 64 1 cm on endoscopy
- Scheduled to undergo endoscopic treatment
- Able and willing to provide written informed consent
You will not qualify if you...
- Previous treatment for gastric adenoma or gastric cancer
- History of gastrectomy
- Diagnosis of gastric cancer or high-grade dysplasia at the time of enrollment
- Presence of multiple gastric adenomas
- Pregnant, breastfeeding, or possibility of pregnancy
- Uncontrolled chronic illnesses that may interfere with trial participation (e.g., uncontrolled hypertension, uncontrolled diabetes, chronic kidney disease, ascites, heart failure, psychiatric disorders)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Day of procedure
Participants undergo either argon plasma coagulation or endoscopic mucosal resection to treat gastric adenoma measuring 1 cm or smaller.
1 treatment visit (in-person)
Follow-up
Duration - 12 months
Participants are monitored with surveillance endoscopies to assess the treated site and check for recurrence.
2 visits (at 3 months and 12 months, in-person)
Trial Site Locations
Total: 3 locations
1
National Cancer Center
Goyang-si, South Korea, 10408
Actively Recruiting
2
Kangbuk Samsung hospital
Seoul, South Korea, 03181
Actively Recruiting
3
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
Loading map...
Research Team
C
Clinical Research Coordinator
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022.
Pedro Pimentel-Nunes, Diogo Libânio, Barbara A J Bastiaansen...
https://pubmed.ncbi.nlm.nih.gov/35523224How Commonly Is the Diagnosis of Gastric Low Grade Dysplasia Upgraded following Endoscopic Resection? A Meta-Analysis.
Guangfeng Zhao, Meng Xue, Yingying Hu...
https://pubmed.ncbi.nlm.nih.gov/26182344Risk of high-grade dysplasia or carcinoma in gastric biopsy-proven low-grade dysplasia: an analysis using the Vienna classification.
S-J Cho, I J Choi, C G Kim...
https://pubmed.ncbi.nlm.nih.gov/21425043Argon plasma coagulation is safe and effective for treating smaller gastric lesions with low-grade dysplasia: a comparison with endoscopic submucosal dissection.
Se Jin Jung, Soo-Jeong Cho, Il Ju Choi...
https://pubmed.ncbi.nlm.nih.gov/23076459